Co-Diagnostics, Inc. (CODX) - Dilution Analysis

S-3 filing: This prospectus relates to the resale of up to 4,942,341 shares of common stock, including PIPE shares and shares issuable upon the exercise of pre-funded and common warrants.

8-K filing: Co-Diagnostics, Inc. entered into a private placement transaction for aggregate gross proceeds of $3.0 million, involving the issuance of common stock and pre-funded warrants. ($3.0M proceeds)

10-Q filing | 3.6M shares outstanding

S-3 filing: The company is filing a shelf registration statement to offer up to $150,000,000 of various securities, including common stock, preferred stock, and debt securities.

10-K filing | 3.6M shares outstanding

8-K filing: Stock split 1-for-30 | Outstanding: 60,892,582 → 2,095,031

10-Q filing | 60.9M shares outstanding

8-K filing: Co-Diagnostics, Inc. entered into a Securities Purchase Agreement to issue and sell 12,002,272 shares of common stock at $0.55 per share and 725,000 pre-funded warrants to purchase 725,000 shares of common stock at $0.5499 per warrant in a registered direct offering. ($7.0M proceeds)

8-K filing: Co-Diagnostics, Inc. entered into a Securities Purchase Agreement to issue and sell 9,619,000 shares of common stock at $0.40 per share in a registered direct offering. ($3.85M proceeds)

10-Q filing | 38.5M shares outstanding

10-Q filing | 32.0M shares outstanding

8-K filing: Co-Diagnostics, Inc. amended its Equity Distribution Agreement with Piper Sandler to include Clear Street LLC as a sales agent; as of April 25, 2025, the Company has sold 833,806 shares under the Equity Distribution Agreement.

10-K filing | 30.3M shares outstanding

10-Q filing | 30.5M shares outstanding

10-Q filing | 30.1M shares outstanding

10-Q filing | 29.8M shares outstanding

10-K filing | 29.3M shares outstanding

10-Q filing | 29.4M shares outstanding

10-Q filing | 29.1M shares outstanding

10-Q filing | 29.5M shares outstanding

10-K filing | 31.5M shares outstanding

S-3 filing: The filing is an S-3 form for a mixed shelf offering of up to $150,000,000 in various securities, including common stock, preferred stock, debt securities, warrants, units and rights. Also includes an ATM offering of common stock up to $50,000,000.

10-Q filing | 31.3M shares outstanding

10-Q filing | 32.5M shares outstanding

10-Q filing | 33.9M shares outstanding

10-K filing | 34.0M shares outstanding

8-K filing: Co-Diagnostics, Inc. entered into agreements to merge with Idaho Molecular, Inc. and Advanced Conceptions, Inc., issuing shares of CODX common stock and warrants as consideration, subject to certain conditions and caps.

10-Q filing | 28.9M shares outstanding

10-Q filing | 28.8M shares outstanding

10-Q filing | 28.7M shares outstanding

10-K filing | 28.0M shares outstanding

10-Q filing | 27.6M shares outstanding

S-3 filing: The Registrant is registering an indeterminate aggregate principal amount and number of securities of each identified class of securities up to a proposed aggregate offering price of $100,000,000, which may be offered from time to time in unspecified numbers and at indeterminate prices, and as may be issuable upon conversion, redemption, repurchase, exchange, or exercise of any securities registered hereunder, including under any applicable anti-dilution provisions.

10-Q filing | 27.6M shares outstanding

10-Q filing | 27.5M shares outstanding

10-K filing | 12.9M shares outstanding

8-K filing: Co-Diagnostics, Inc. entered into Securities Purchase Agreements with certain institutional investors for the sale of 470,000 shares of common stock at $9.00 per share, with gross proceeds expected to be approximately $4,230,000. ($4.23M proceeds)

8-K filing: The Company closed its previously announced registered direct offering of 3,324,676 shares of its common stock at a purchase price per share of $3.08, for gross proceeds of approximately $10.2 million. ($10.2M proceeds)

8-K filing: Co-Diagnostics, Inc. entered into Securities Purchase Agreements with certain institutional investors for the sale of 3,324,676 shares of common stock at a purchase price of $3.08 per share in a registered direct offering, with aggregate gross proceeds expected to be approximately $10.24 million. ($10.24M proceeds)

8-K filing: Co-Diagnostics, Inc. entered into Securities Purchase Agreements for the sale of 3,448,278 shares of common stock at $1.45 per share in a registered direct offering, with gross proceeds expected to be approximately $5,000,000. ($5.0M proceeds)